AVCT (AVCT) News
Follow AVCT (AVCT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Avacta Group plc (AVCT) Posts H1 Loss, Plans Capital Raise; Cash Runway Into Early Q1 2027
Avacta reported an unaudited H1 2026 operating loss of £13.91M, cash of £20.27M at 30 Jun (£10.59M at 31 Aug), ~£19.0M raised YTD, and plans a new capital raise. Convertible bond debt was £15.77M with £3.29M derivative;
NEWS | Sep 30, 2026, 12:09 PM UTC
L
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
LONDON and PHILADELPHIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today publishes its unaudited
NEWS | Sep 30, 2026, 12:08 PM UTC
L
Avacta Therapeutics Announces Intention To Use AIM Capital Access Window For Equity Fundraise
Avacta Group PLC LSE:AVCT
NEWS | Sep 30, 2026, 06:48 AM UTC
L
Avacta Group plc (AVCT) Shares Early AVA6103 Phase 1 Safety/PK And PDAC Preclinical Data
Avacta detailed FOCUS-01 Phase 1 design and preclinical PDAC data for AVA6103, noting preliminary safety and PK consistent with models and tolerability up to ~50% above conventional exatecan MTD. Initial efficacy readout
EQUITY | Sep 25, 2026, 06:09 AM UTC
L
Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
LONDON and PHILADELPHIA, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, the "Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today announces the presentati
NEWS | Sep 25, 2026, 06:08 AM UTC
M
Avacta says AVA6103 candidate shows proof of mechanism in Phase 1
Avacta Group PLC said its AVA6103 drug candidate achieved proof of mechanism in a Phase 1 trial.
EQUITY | Sep 16, 2026, 04:36 PM UTC
L
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
LONDON and PHILADELPHIA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics AIM:AVCT, a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced t
NEWS | Sep 14, 2026, 06:01 AM UTC
L
REG - Avacta Group PLC - Mats Blom to Board as Chair of Audit Committee
RNS Number: 5140U Avacta Group PLC 14 September 2026 Avacta Group plc("Avacta" or the "Company")Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit CommitteeLONDON and PHILADELPHIA - September 14, 2026
NEWS | Sep 14, 2026, 06:00 AM UTC
L
Avacta reports accelerated payment of convertible bond installment
Avacta Therapeutics says it has completed an accelerated amortized payment of a convertible bond installment.
EQUITY | Sep 04, 2026, 06:00 AM UTC
L
Avacta Group PLC share option awards to management team
Avacta Group PLC will make share option awards to its management team at Avacta.
EQUITY | Sep 01, 2026, 06:01 AM UTC